Lecturers

Senu Apewokin, Ph.D. University of Cinncinatti  Microbiome Science: Asking bedside questions at the bench

Senu Apewokin, Ph.D.
University of Cinncinatti

Microbiome Science: Asking bedside questions at the bench



Christian Buchholz, Ph.D. Paul-Ehrlich-Institut, Langen, Germany   In Vitro Generation of CAR T cells

Christian Buchholz, Ph.D.
Paul-Ehrlich-Institut, Langen, Germany

In Vitro Generation of CAR T cells


Karin Gaensler, M.D. UCSF   Immune gene therapy of cancer – tumour cells as cancer vaccines

Karin Gaensler, M.D.
UCSF

Immune gene therapy of cancer – tumour cells as cancer vaccines

Beth Helmink, Ph.D. MD Anderson   Bringing concepts to clinic--the role of the gut microbiome in the response to immune checkpoint blockade in melanoma patients

Beth Helmink, Ph.D.
MD Anderson

Bringing concepts to clinic--the role of the gut microbiome in the response to immune checkpoint blockade in melanoma patients

Martin Pule, Ph.D. University College London -Autolus   CAR T-cell therapy for ALL

Martin Pule, Ph.D.
University College London -Autolus

CAR T-cell therapy for ALL

Ravid Straussman, Ph.D.  The Weizmann Institute  The tumor microbiome and its effects on resistance to anti-cancer therapies

Ravid Straussman, Ph.D.
The Weizmann Institute

The tumor microbiome and its effects on resistance to anti-cancer therapies

David Boothman, Ph.D.  Indiana University School of Medicine  Exploiting the NQO1 bioactivatable ‘kiss of death’ for lung and pancreatic cancer therapies

David Boothman, Ph.D.
Indiana University School of Medicine

Exploiting the NQO1 bioactivatable ‘kiss of death’ for lung and pancreatic cancer therapies

Laura Conforti, Ph.D. University of Cincinnati   Targeting ion channels to overcome the immunosuppressive tumor microenvironment

Laura Conforti, Ph.D.
University of Cincinnati

Targeting ion channels to overcome the immunosuppressive tumor microenvironment

Naama Geva-Zatorsky, Ph.D.  Technion Integrated Cancer Center   The gut microbiota as immuno-modulatory agents

Naama Geva-Zatorsky, Ph.D.
Technion Integrated Cancer Center

The gut microbiota as immuno-modulatory agents

Michael Hust, Ph.D. Technische Universität Braunschweig  Fighting Pathogens and Toxins with human and human-like recombinant Antibodies

Michael Hust, Ph.D.
Technische Universität Braunschweig

Fighting Pathogens and Toxins with human and human-like recombinant Antibodies

Caetano Reis e Sousa, Ph.D. The Francis Crick Institute   Dendritic cells as a checkpoint in anti-cancer immunity

Caetano Reis e Sousa, Ph.D.
The Francis Crick Institute

Dendritic cells as a checkpoint in anti-cancer immunity

Jonathon Swann, Ph.D. Imperial College  Gut microbiota and their biochemical communication with the host

Jonathon Swann, Ph.D.
Imperial College

Gut microbiota and their biochemical communication with the host

Thomas Blankenstein, Ph.D.  Max Delbrück Center for Molecular Medicine  T cell receptor gene therapy

Thomas Blankenstein, Ph.D.
Max Delbrück Center for Molecular Medicine

T cell receptor gene therapy



Andrew Deng, Ph.D. Bristol-Myers Squibb   Utilizing cytokines in immuno-therapy

Andrew Deng, Ph.D.
Bristol-Myers Squibb

Utilizing cytokines in immuno-therapy


Amato Giaccia, Ph.D.  Stanford   The past, present and future of combining radiotherapy and immune therapy

Amato Giaccia, Ph.D.
Stanford

The past, present and future of combining radiotherapy and immune therapy


Randolph J Noelle, Ph.D. Geisel School of Medicine at Dartmouth  VISTA: a novel checkpoint regulator of innate and adaptive immunity

Randolph J Noelle, Ph.D.
Geisel School of Medicine at Dartmouth

VISTA: a novel checkpoint regulator of innate and adaptive immunity

Andrew Sewell Ph.D.  University of Cardiff   New modes of T-cell recognition by dissection of successful cancer immunotherapy ”

Andrew Sewell Ph.D.

University of Cardiff

New modes of T-cell recognition by dissection of successful cancer immunotherapy

Thomas Thompson, Ph.D.  University of Cinncinatti  Therapeutic modulation of the TGFß Superfamily

Thomas Thompson, Ph.D.
University of Cinncinatti

Therapeutic modulation of the TGFß Superfamily

Alex Bullock, Ph.D. University of Oxford  Affordable drug development for paediatric brain tumors

Alex Bullock, Ph.D.
University of Oxford

Affordable drug development for paediatric brain tumors



Gerard Evan, Ph.D. Caimbridge University

Gerard Evan, Ph.D.
Caimbridge University



Adrian Hayday, Ph.D. Kings College London

Adrian Hayday, Ph.D.
Kings College London






Hardev Pandha, Ph.D. University of Surrey   Oncolytic viral vectors in the clinic

Hardev Pandha, Ph.D.
University of Surrey

Oncolytic viral vectors in the clinic


Leonard Seymour, Ph.D. University of Oxford   Targeting immunotherapy using oncolytic viruses

Leonard Seymour, Ph.D. University of Oxford

Targeting immunotherapy using oncolytic viruses

Thorbald van Hall, Ph.D. Leiden University Medical Center  NKG2A as a novel checkpoint for cancer immunotherapy

Thorbald van Hall, Ph.D. Leiden University Medical Center

NKG2A as a novel checkpoint for cancer immunotherapy

Organizing Committee:

Farzin Farzaneh
Peter Stambrook

Executive Committee: 
Stephania Cormier
Jessica Homa
James Kang
Thomas Thompson
Warren Zimmer

FULL PROGRAM